Protection of Defence personnel against health risks of chromium-6 was inadequate From 1984-2006, employees of the Dutch Ministry of Defence were exposed to chromium-6 during maintenance work.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
More gonorrhoea, syphilis and chlamydia at Dutch STI clinics An increasing number of clients tested at a Dutch STI clinic for a sexually transmitted infection (STI) is diagnosed with gonorrhoea, syphilis and chlamydia.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
The number of STI tests keeps increasing The number of clients tested for sexually transmitted infections (STIs) at Dutch STI clinics has increased since 2004.
Improving consumer exposure assessment to chemical substances By combining the available international knowledge, the method to assess the extent to which consumers are exposed to chemical substances via everyday products such as paint, cleaning agents and co
Risks of chemical substances to human health and the environment RIVM is developing methods to identify new and emerging risks of chemical substances to workers, consumers and the environment.
Is screening for sexually transmitted infections as part of HIV care cost-effective in the Netherlands? Routine screening for anorectal chlamydia among HIV-positive men who have sex with men (MSM) could avert further spread of chlamydia and HIV in the total MSM population.